# Investment Dossier: JAZZ
**Rank: #2 | Composite Score: 8.30/10**
**Generated: 2026-01-05 (as-of date)**

## Executive Summary
- Company: Jazz Pharmaceuticals plc
- Price: $174.39
- Market Cap: $10.60B
- Cash: $1326M
- Clinical Stage: commercial
- Active Trials: 11/50

## Score Breakdown

| Component | Score | Weight | Contribution |
|-----------|-------|--------|--------------|
| Stage | 10.0/10 | 30% | 3.00 |
| Cash (capped) | 6.5/10 | 25% | 1.63 |
| Runway | 10.0/10 | 25% | 2.50 |
| Pipeline | 5.9/10 | 20% | 1.17 |
| **Composite** | **8.30/10** | 100% | **8.30** |

## Financial Reality Check
- Cash: $1326M
- Estimated Runway: 60+ mo (capped)
- Market Cap: $10.60B
- Daily Volume: 902,201 shares

## Freshness & Point-in-Time Discipline

**As-of Date:** 2026-01-05

**SEC Financial Data:**
- Period End: 2025-10-01
- Period End Age: 96 days
- Filed Date: 2026-01-05
- Status: FRESH (<365 days)

**Market Data:**
- Source: Yahoo Finance (real-time)
- Last Update: 2026-01-05

## Data Quality
- Overall Coverage: 93%
- Financial Coverage: 100%
- SEC Data Status: Fresh

## Risk Warnings
- [NOTE] Runway capped at 60mo for scoring (prevents burn artifacts)

---
*Point-in-time validated. Algorithmically generated. Verify all data before investment decisions.*
